Rectify Pharma

Rectify Pharmaceuticals is a biotechnology company focused on developing novel small molecule therapies that target ABC transporters, a family of membrane-bound proteins crucial for various bodily functions. The company's unique approach centers around "Positive Functional Modulators" (PFMs), which are designed to restore and enhance the function of ABC transporters, addressing the underlying cause of numerous diseases. Rectify's ambition is to deliver transformative treatments for patients suffering from both rare and common disorders associated with ABC transporter dysfunction, including liver, biliary, eye, central nervous system, and cardiometabolic diseases.

Rectify has assembled a team of seasoned scientists and biotech leaders, attracting talent from renowned institutions and companies. The company has secured significant funding through a Series A financing round led by prominent venture capital firms, enabling them to advance their pipeline of PFMs towards clinical trials. The company's commitment to scientific innovation and patient-centric approach positions them as a frontrunner in the field of ABC transporter-targeted therapies.

Rectify Pharmaceuticals is a biotechnology company focused on developing small molecule disease-modifying therapeutics that restore and enhance ABC transporter function, ultimately addressing the underlying cause of serious ABC transporter-mediated diseases. The company is pioneering a new approach to treating a wide range of genetic and common diseases by targeting this critical class of membrane proteins, with a mission to provide life-changing therapies to patients in need.

Rectify Pharma cultivates a culture of passion, drive, and collaboration. It emphasizes the importance of its team members' commitment to restoring hope for individuals and families affected by serious ABC transporter mediated diseases. The company values its team of scientists and biotech leaders, fostering a collaborative environment where innovation and a shared vision thrive.